Global rheumatoid arthritis (RA) treatment market will reach $19.3 billion in 2023

Global rheumatoid arthritis (RA) treatment market will reach $19.3 billion in 2023

April 30, 2015 Source: Bio Valley

GlobalData, a world-renowned market research company, released a research report that in the next 10 years (2013-2023), the global rheumatoid arthritis (RA) treatment market will grow steadily with a CAGR of 2.1%, reaching by 2023. With $19.3 billion, the market had a market capitalization of $15.6 billion in 2013. Among the top 10 pharmaceutical markets in the world, the United States is the largest RA treatment market, with a global market share of 67% in 2013. By the end of 2023, despite a slight decline in the US market share (65%), the country will maintain its leading position in the global RA treatment market.

Rheumatoid arthritis (RA) is an attractive therapeutic area for major pharmaceutical companies, and the market is currently dominated by expensive anti-TNF biologics that can Effectively treats the signs and symptoms of RA and can suppress the deterioration of the condition. However, the launch of biosimilars, new biologics, and oral JAK inhibitors is rapidly changing the clinical treatment modalities of RA and impacting the sale of TNF biologics. However, in view of the outstanding efficacy of anti-TNF biologics in the treatment of RA, the newly listed products will face an extremely fierce market competition, and will also face further threats from biosimilars.

The report points out that the main factors driving the growth of the global RA treatment market in the next 10 years include: increased incidence of RA and expected listing of multiple new drugs, including three interleukin-6 (IL-6) inhibitors and four novel organisms. Formulations, 4 Janus kinase (JAK) inhibitors, and numerous biosimilars. Drugs with novel mechanisms of action (including biologics and small molecule drugs) will be welcomed by the market, but it is foreseeable that the global RA treatment market will become increasingly crowded. Major pharmaceutical companies need strong clinical data and clear development and commercialization strategies to better penetrate new products into the already competitive market.

The report points out that new biologics and oral JAK inhibitors that are about to enter the market are expected to be sold at a small discount. Perhaps the most anticipated in the RA market is biosimilars, which will create price pressures in the market, selling prices. Expected to be about 30% lower than branded drugs, it will provide patients with cheaper treatment options. However, the current biosimilars market is still in its infancy, and there are still many controversies surrounding the patent and regulatory approaches to biosimilars, and the question of how to properly use biosimilars from doctors and regulators remains, which will limit patients. Access to biosimilars. However, once the initial stage of the problem is resolved, biosimilars will flood the market and will compete for market share of branded drugs, including Enbrel from Enjin/Pfizer/Wutian, Humira from Abbott, and Bristol-Myers/Ono. Orencia will also constrain the growth of the global RA treatment market.